| A | B | C | D | E | F | G | H | I | |
|---|---|---|---|---|---|---|---|---|---|
1 | CLINICAL TRIALS | ||||||||
2 | PROSTATE CANCER - Advanced and Recurrent | ||||||||
3 | Source: clinicaltrials.gov | ||||||||
4 | ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process. | ||||||||
5 | Contact Information | ||||||||
6 | No. | Link | Title | Official Title | Purpose | Citation | Organization/Sponsor | Collaborator | Status |
7 | |||||||||
8 | 1 | http://clinicaltrials.gov/ct2/show/NCT00450619 | 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer | A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00450619 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | |
9 | 2 | http://clinicaltrials.gov/ct2/show/NCT01320787 | 18-F-Fluoroacetate as PET Imaging Agent | A Phase I Study of 18-F-Fluoroacetate Sodium as a PET Imaging Agent for Tumor Detection | The goal of this clinical research study is to find out the highest tolerable dose of an imaging solution called 18-F-fluoroacetate sodium that can be given before a positron emission tomography (PET) scan. The safety of this solution will also be studied. | http://clinicaltrials.gov/ct2/show/NCT01320787 - Retrieved November 2011 | M.D. Anderson Cancer Center | Not yet recruiting | |
10 | 3 | http://clinicaltrials.gov/ct2/show/NCT01383863 | A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer (TRIPTOCARE LT) | A Prospective Observational Study Cohort to Assess the Rate of Castration Resistance, Disease Progression and Overall Survival Over a 3-year Period Post-androgen Deprivation Therapy Induction in Patients With Advanced Prostate Cancer Who Have Previously Participated in the Triptocare Study (Http://Clinicaltrials.Gov/ct2/Show/Study/NCT01020448) | The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy induction in a study cohort of patients with advanced disease. | http://clinicaltrials.gov/ct2/show/NCT01383863 - Retrieved November 2011 | Ipsen | Not yet recruiting | |
11 | 4 | http://clinicaltrials.gov/ct2/show/NCT00772317 | A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU (STAR | A Multicenter Clinical Study of the Sonablate® 500 (Sonablate) for the Treatment of Locally Recurrent Prostate Cancer With HIFU | For the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT) | http://clinicaltrials.gov/ct2/show/NCT00772317 - Retrieved November 2011 | USHIFU, LLC | Currently recruiting | |
12 | 5 | http://clinicaltrials.gov/ct2/show/NCT01094288 | A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | This is an open-label, multicenter, Phase 1 study that will evaluate the safety and tolerability of MLN8237 given orally in combination with docetaxel as a treatment for advanced solid tumors to determine tolerable doses and schedules of MLN8237 and docetaxel to be evaluated in future Phase 2 studies. | http://clinicaltrials.gov/ct2/show/NCT01094288 - Retrieved November 2011 | Millennium Pharmaceuticals, Inc. | Currently recruiting | |
13 | 6 | http://clinicaltrials.gov/ct2/show/NCT01337518 | A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer | A Phase 1a/1b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients With Castration-Resistant Prostate Cancer | This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC). Goals of this phase I study include finding out the dose of EZN-4176 that can be safely given without serious side effects and to determine the amount of EZN-4176 that should be given in future studies. | http://clinicaltrials.gov/ct2/show/NCT01337518 - Retrieved November 2011 | Enzon Pharmaceuticals, Inc. | Currently recruiting | |
14 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00503984 | A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients Previously Treated With Docetaxel | A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen. | This phase I/II trial is studying the side effects and best dose of azacitidine and docetaxel when given together with prednisone and to see how well they work in treating patients with metastatic prostate cancer that did not respond to hormone therapy. | http://clinicaltrials.gov/ct2/show/NCT00503984 - Retrieved November 2011 | University of Miami Sylvester Comprehensive Cancer Center | Currently recruiting | |
15 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01331083 | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer | The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause. | http://clinicaltrials.gov/ct2/show/NCT01331083 - Retrieved November 2011 | NCIC Clinical Trials Group | Oncothyreon Canada Inc. | Currently recruiting |
16 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01306890 | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED) | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer | The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival. | http://clinicaltrials.gov/ct2/show/NCT01306890 - Retrieved November 2011 | Dendreon | Currently recruiting | |
17 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01325558 | A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors | A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors | This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors. The purpose of this study is to determine the maximum tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given with gemcitabine. The clinical benefit, progression-free survival and overall survival of study participants will also be assessed. | http://clinicaltrials.gov/ct2/show/NCT01325558 - Retrieved November 2011 | Altor Bioscience Corporation | Currently recruiting | |
18 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01300533 | A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer | A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer | The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer | http://clinicaltrials.gov/ct2/show/NCT01300533 - Retrieved November 2011 | BIND Biosciences | Currently recruiting | |
19 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01191775 | A Study of PNT2258 in Patients With Advanced Solid Tumors | A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumo | The purpose of this research study is to evaluate the safety of the investigational drug PNT2258 in patients with advance tumors and see how it acts in the body. | http://clinicaltrials.gov/ct2/show/NCT01191775 - Retrieved November 2011 | Pronai Therapeutics, Inc | Currently recruiting | |
20 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01228760 | A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Advanced Prostate Cancer | A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Advanced Prostate Cance | The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01228760 - Retrieved November 2011 | Astellas Pharma Inc | Seattle Genetics, Inc. | Currently recruiting |
21 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... | A Targeted Ph I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade (Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC) | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00923247 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | |
22 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01309672 | Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II | This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy | http://clinicaltrials.gov/ct2/show/NCT01309672 - Retrieved November 2011 | Southwest Oncology Group | National Cancer Institute | Currently recruiting |
23 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01023061 | Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer | Phase II Trial of Radiation With Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent With Radiation Therapy | This phase II trial is studying the side effects and how well giving abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced prostate cancer | http://clinicaltrials.gov/ct2/show/NCT01023061 - Retrieved November 2011 | Fred Hutchinson Cancer Research Center | National Cancer Institute | Currently recruiting |
24 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00892736 | ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With BRCA ½ -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer | This phase I trial is studying the side effects and best dose of ABT-888 in treating patients with malignant solid tumors that did not respond to previous therapy. | http://clinicaltrials.gov/ct2/show/NCT00892736 - Retrieved November 2011 | University of Pittsburgh | National Cancer Institute | Currently recruiting |
25 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00890006 | Advanced Imaging for Radiotherapy Treatment Planning and Guidance for Low-Intermediate Risk Prostate Cancer (Margin) | Low-Intermediate Risk Prostate Cancer: Improving Acute Toxicity Outcomes of Radiotherapy With the Integration of Advanced Imaging for Treatment Planning and Guidance | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00890006 - Retrieved November 2011 | University Health Network, Toronto | Currently recruiting | |
26 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00309985 | Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer | CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] | This randomized phase III trial is studying androgen ablation therapy and chemotherapy to see how well they work compared to androgen ablation therapy alone in treating patients with metastatic prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00309985 - Retrieved November 2011 | Eastern Cooperative Oncology Group | National Cancer Institute | Currently recruiting |
27 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00796458 | Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer | Phase III Study of Chemo-Hormonal Therapy Versus Hormonal Therapy Alone in Advanced Hormone-Naives Prostate Cancer Patients. | This randomized phase III trial is studying androgen ablation and docetaxel to see how well they work compared with androgen ablation alone in treating patients with advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00796458 - Retrieved November 2011 | Rete Oncologica Piemontese - Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino | Currently recruiting | |
28 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01220973 | Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | Phase II Trial of Atorvastatin and Celecoxib in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer. | This phase II trial is studying how well giving atorvastatin calcium together with celecoxib works in treating patients with rising PSA levels after local therapy for prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01220973 - Retrieved November 2011 | Cancer Institute of New Jersey | National Cancer Institute | Currently recruiting |
29 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01320280 | BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer | Single-arm, Open-label, Single-center Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer After Failure of Treatment With Docetaxel or Ineligible for Treatment With Docetaxel | The purpose of this study is to find out what effects, good and/or bad, BIBW 2992 (Afatinib) has on patients and their advanced prostate cancer which does not respond to hormone or chemotherapy any more. Only patients with tumors which have an increased amounts of a protein called HER2 on their cell surface will be included. BIBW 2992 (Afatinib) is a drug which in advanced clinical testing in lung and breast cancer. | http://clinicaltrials.gov/ct2/show/NCT01320280 - Retrieved November 2011 | Universitätsklinikum Hamburg-Eppendorf | Boehringer Ingelheim Pharmaceuticals | Not yet recruiting |
30 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | A Randomized Phase II Study of Combined Androgen Deprivation Versus Combined Androgen Deprivation With IMC-A12 for Patients With New Hormone-Sensitive Metastatic Prostate Cancer | This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01120236 - Retrieved November 2011 | Southwest Oncology Group | National Cancer Institute | Currently recruiting |
31 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01200810 | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | A Randomized Phase II Study of Peripheral Androgen Blockade With Bicalutamide Followed by Placebo or Treatment With the Gamma Secretase Inhibitor RO4929097 in Men With Rising PSA After Definitive Local Therapy for Adenocarcinoma of the Prostate | This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer | http://clinicaltrials.gov/ct2/show/NCT01200810 - Retrieved November 2011 | Cancer Institute of New Jersey | National Cancer Institute | Currently recruiting |
32 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01251861 | Bicalutamide With or Without MK2206 in Treating Patients With Previously Treated Prostate Cancer | Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy | This phase II clinical trial is studying how well giving bicalutamide with or without MK2206 works in treating patients with previously treated prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01251861 - Retrieved November 2011 | Eastern Cooperative Oncology Group | National Cancer Institute | Currently recruiting |
33 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01417182 | Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer | Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT01417182 - Retrieved November 2011 | Sidney Kimmel Comprehensive Cancer Center | Currently recruiting | |
34 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01275651 | Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole | Androgen Receptor (AR) Activity in Castration-Resistant Prostate Cancer (CRPC) and Response to Ketoconazole | This laboratory study is studying biomarkers in bone marrow and blood samples from patients with prostate cancer treated with ketoconazole. | http://clinicaltrials.gov/ct2/show/NCT01275651 - Retrieved November 2011 | Cancer and Leukemia Group B | National Cancer Institute | Not yet recruiting |
35 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01120262 | Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin | Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy | This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin. | http://clinicaltrials.gov/ct2/show/NCT01120262 - Retrieved November 2011 | Southwest Oncology Group | National Cancer Institute | Not yet recruiting |
36 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiving chemotherapy for prostate cancer | http://clinicaltrials.gov/ct2/show/NCT01469338 - Retrieved November 2011 | USC/Norris Comprehensive Cancer Center | National Cancer Institute; Sanofi-Aventis | Currently recruiting |
37 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01420250 | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT01420250 - Retrieved November 2011 | Thomas Jefferson University | Sanofi-Aventis | Currently recruiting |
38 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors. | http://clinicaltrials.gov/ct2/show/NCT01466036 - Retrieved November 2011 | Massachusetts General Hospital | Not yet recruiting | |
39 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00536991 | Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer | A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer | This phase I/II trial is studying the side effects and best dose of calcitriol when given together with ketoconazole and hydrocortisone and to see how well it works in treating patients with advanced or recurrent prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00536991 - Retrieved November 2011 | Roswell Park Cancer Institute | Department of Defense | Currently recruiting |
40 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00918645 | Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis | Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease | This clinical trial is studying how well calcium-41 (41Ca) chloride aqueous solution works in diagnosing patients with prostate cancer and bone metastasis. | http://clinicaltrials.gov/ct2/show/NCT00918645 - Retrieved November 2011 | University of California, Davis | National Cancer Institute | Currently recruiting |
41 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01051570 | Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | Phase II Trial of Carboplatin and RAD001 in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy. | This phase II trial is studying how well giving carboplatin together with everolimus and prednisone works in treating patients with metastatic prostate cancer that progressed after docetaxel. | http://clinicaltrials.gov/ct2/show/NCT01051570 - Retrieved November 2011 | Barbara Ann Karmanos Cancer Institute | National Cancer Institute | Currently recruiting |
42 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01260688 | Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel | A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer | This randomized phase II trial is studying the side effects and how well giving cediranib maleate together with or without dasatinib works in treating patients with hormone-resistant prostate cancer resistant to treatment with docetaxel. | http://clinicaltrials.gov/ct2/show/NCT01260688 - Retrieved November 2011 | Princess Margaret Hospital, Canada | National Cancer Institute | Currently recruiting |
43 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00928252 | Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer | Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer | The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory) metastatic prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00928252 - Retrieved November 2011 | Queen's Medical Centre | National Cancer Institute | Currently recruiting |
44 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy | This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01054079 - Retrieved November 2011 | Wake Forest University | Currently recruiting | |
45 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration- Resistant Prostate Cancer (CRPC) | This phase I/II trial is studying the side effects of giving cixutumumab together with temsirolimus and to see how well it works in treating patients with metastatic prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01026623 - Retrieved November 2011 | Memorial Sloan-Kettering Cancer Center | National Cancer Institute | Currently recruiting |
46 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00851916 | CyberKnife Radiosurgery for Locally Recurrent Prostate CA | VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY | The purpose of this study is to scientifically evaluate the effects (good and bad) of a new type of radiation treatment in patients with locally recurrent prostate cancer after prior radiotherapy. The treatment is known as prostate radiosurgery, and is distinguished from traditional radiotherapy by the application of smaller, more precisely controlled margins around the area targeted for full dose radiation, and far fewer treatments, using a much larger dose per treatment. This research is being done to see what advantages, if any, prostate radiosurgery may have over other salvage treatment methods, including brachytherapy, cryosurgery, high intensity focused ultrasound (HIFU), hormonal therapy and radical prostatectomy. | http://clinicaltrials.gov/ct2/show/NCT00851916 - Retrieved November 2011 | CyberKnife Centers of San Diego | Currently recruiting | |
47 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01417676 | DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study (Propel) | Pelvic Lymph Node Irradiation With Simultaneous Integrated Boost to Prostate for High Risk Prostate Cancer Patients: A Phase I/II Study | This is a prospective, open label 1 arm study, multicentre, Phase I/II clinical safety study. The trial is designed to gain initial safety and efficacy data on pelvic lymph node radiation with simultaneous integrated boost to prostate in high risk prostate cancer patients. | http://clinicaltrials.gov/ct2/show/NCT01417676 - Retrieved November 2011 | University of Aarhus | Rigshospitalet, Denmark; Herlev Hospital; Odense University Hospital; Vejle Hospital; Aalborg Hospital; Danish Center for Interventional Research in Radiation Oncology (CIRRO | Currently recruiting |
48 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00792545 | Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery | A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors | This phase I trial is studying the side effects and best dose of dasatinib given together with bevacizumab in treating patients with solid tumor that is metastatic or cannot be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT00792545 - Retrieved November 2011 | National Cancer Institute | Currently recruiting | |
49 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01162135 | Digoxin for Recurrent Prostate Cancer | A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA | The purpose of this study is to assess the effectiveness of dioxin on prohibiting prostate cancer progression as measured by PSADT (prostate-specific antigen doubling time). | http://clinicaltrials.gov/ct2/show/NCT01162135 - Retrieved November 2011 | Thomas Jefferson University | Currently recruiting | |
50 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01145508 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer | This randomized phase II trial is studying giving docetaxel and prednisone together with or without vaccine therapy to see how well it works in treating patients with metastatic hormone-resistant prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01145508 - Retrieved November 2011 | Eastern Cooperative Oncology Group | National Cancer Institute | Currently recruiting |
51 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01054313 | Docetaxel and Sirolimus in Patients With Advanced Malignancies | A Phase I Trial of Docetaxel and Sirolimus in Patients With Advanced Malignancies | The goal of this clinical research study to find the highest tolerated dose of the combination of Taxotere (docetaxel) and Rapamycin (sirolimus) when given to patients with advanced cancer. Researchers also want to find highest tolerated dose of the combination of docetaxel, sirolimus, and prednisone when given to patients with advanced prostate cancer. The safety of both drug combinations will also be studied. | http://clinicaltrials.gov/ct2/show/NCT01054313 - Retrieved November 2011 | M.D. Anderson Cancer Center | Currently recruiting | |
52 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC). | This phase I/II trial studies the side effects and best dose of pasireotide and to see how well it works when given together with docetaxel and prednisone in treating patients with metastatic hormone-resistant prostate cancer. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pasireotide may inhibit the secretion of hormones. Giving pasireotide together with docetaxel and prednisone may kill more tumor cells. | http://clinicaltrials.gov/ct2/show/NCT01468532 - Retrieved November 2011 | Barbara Ann Karmanos Cancer Institute | National Cancer Institute | Currently recruiting |
53 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01436214 | Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer | This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01436214 - Retrieved November 2011 | Adamis Pharmaceuticals Corporation | Currently recruiting | |
54 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT01240629 - Retrieved November 2011 | USC/Norris Comprehensive Cancer Center | AEterna Zentaris | Currently recruiting |
55 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00668642 | Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer | Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer | The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy | http://clinicaltrials.gov/ct2/show/NCT00668642 - Retrieved November 2011 | NorthShore University HealthSystem Research Institute | University of Chicago; Northwestern University | Currently recruiting |
56 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01326312 | Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer (GTx758) | Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist | The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01326312 - Retrieved November 2011 | GTx | Currently recruiting | |
57 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01346839 | Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care | Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care | Diagnostic delays in ambulatory care are often due to breakdowns of related care processes. Electronic systems can improve follow-up and reduce delays by detecting missed appointments or incomplete procedures so that patients are called back to conduct timely investigations when appropriate. To achieve high standards of patient safety in cancer diagnosis, the investigators not only need to use information technology appropriately but also improve the processes, policies, and procedures of monitoring, communication, and coordination of care. Given the importance of cancer-related diagnostic delays in ambulatory care, the investigators need effective methods to detect them, understand their causes, and intervene to reduce them. Manual techniques to detect these delays, such as spontaneous reporting and random chart reviews, have limited effectiveness. Our proposed study focuses on testing methods to proactively identify delays using certain "triggers" as they occur and intervene in a timely manner. | http://clinicaltrials.gov/ct2/show/NCT01346839 - Retrieved November 2011 | Baylor College of Medicine Scott and White Hospital & Clinic | Currently recruiting | |
58 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00411853 | Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients | An Open Phase II Clinical Trial of Fermented Wheat Germ Extract in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00411853 - Retrieved November 2011 | Sheba Medical Center | Currently recruiting | |
59 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01257425 | Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg (PAMIS) | A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer | The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01257425 - Retrieved November 2011 | Ipsen | Currently recruiting | |
60 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00943956 | Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer | A Phase I Trial to Evaluate Acute and Late Toxicities of Concurrent Treatment With Everolimus (RAD001) and Radio-Hormonotherapy in High-risk Prostate Cancer. | This phase I trial is studying the side effects and best dose of everolimus when given together with bicalutamide and leuprolide acetate in treating patients with high-risk locally advanced prostate cancer undergoing radiation therapy. | http://clinicaltrials.gov/ct2/show/NCT00943956 - Retrieved November 2011 | Centre Val d'Aurelle - Paul Lamarque | Currently recruiting | |
61 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00882609 | F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets | 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques | The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT will lead to improved treatment and patient outcomes. | http://clinicaltrials.gov/ct2/show/NCT00882609 - Retrieved November 2011 | American College of Radiology - Image Metrix | Academy of Molecular Imaging | Currently recruiting |
62 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00562315 | FACBC PET/CT for Recurrent Prostate Cancer | 18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01). | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00562315 - Retrieved November 2011 | David M. Schuster, MD | Currently recruiting | |
63 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer | Anti-[18F]FACBC PET-CT for the Characterization of Primary Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00917865 - Retrieved November 2011 | David M. Schuster, MD | Currently recruiting | |
64 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01254513 | Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients (GERICO10) | Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), "Vulnerable" or "Frail" , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG) | The objective of this study is to evaluate the feasibility of two different chemotherapy protocols with adjusted doses for patients aged 75 and over who often have medical problems other than prostate cancer. Patient will receive Docetaxel either every 3 weeks or weekly. In both cases, chemotherapy is combined with prednisone. The protocol will be considered feasible when patient will receive 6 cycles of chemotherapy (1 cycle = 3 weeks). Additionally to this primary objective, efficacy will also be evaluated for both protocols as well as tolerance to treatment, quality of life and evolution of geriatric data. | http://clinicaltrials.gov/ct2/show/NCT01254513 - Retrieved November 2011 | Federation Nationale des Centres de Lutte Contre le Cancer | Currently recruiting | |
65 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00936975 | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases | A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases (BMS #180-279) | This phase II trial is studying how well fluorine F 18 sodium fluoride PET works in evaluating response to dasatinib in patients with prostate cancer and bone metastases. | http://clinicaltrials.gov/ct2/show/NCT00936975 - Retrieved November 2011 | American College of Radiology Imaging Network | National Cancer Institute | Currently recruiting |
66 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma | This randomized phase III trial is studying gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, cisplatin, and placebo in treating patients with advanced urinary tract cancer. | http://clinicaltrials.gov/ct2/show/NCT00942331 - Retrieved November 2011 | Cancer and Leukemia Group B | National Cancer Institute | Currently recruiting |
67 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy | Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine | This phase I trial is studying the side effects and best dose of gene therapy given together with radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy. | http://clinicaltrials.gov/ct2/show/NCT00788307 - Retrieved November 2011 | Mayo Clinic | National Cancer Institute | Currently recruiting |
68 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01126879 | Genistein in Treating Patients With Prostate Cancer | Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells | This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01126879 - Retrieved November 2011 | Northwestern University | National Cancer Institute | Currently recruiting |
69 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00769223 | Gleason Score, Prostate-Specific Antigen Level, and Cancer Stage in Predicting Outcome in Patients Who Have Undergone Radiation Therapy for Localized Prostate Cancer | Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer | This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00769223 - Retrieved November 2011 | University of California, San Francisco | National Cancer Institute | Currently recruiting |
70 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00685516 | Green Tea, Decaffeinated Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery | A Phase II Randomized, Open-Label, Three-Arm Study of Green Tea, Black Tea and a Water Control in Men Scheduled for Prostatectomy | This randomized phase II trial is studying green tea to see how well it works compared with decaffeinated black tea or water in treating patients with prostate cancer undergoing surgery. | http://clinicaltrials.gov/ct2/show/NCT00685516 - Retrieved November 2011 | University of California, Los Angeles | National Cancer Institute | Currently recruiting |
71 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00669656 | Herbal Therapy for Treatment of Recurrent Prostate Cancer | A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy | This study is about Prostate Health Cocktail, a combination supplement that contains vitamin D3, vitamin E, selenium, green tea extract, saw palmetto, lycopene, and soy derivatives. This product is currently available on the market, as herb and vitamin supplements are not regulated by the FDA. Each ingredient has been studied in prostate cancer cells and/or in patients with prostate cancer. At the doses included in this supplement, no serious side effects have been reported. The purpose of this study is to find out whether Prostate Health Cocktail can lower your PSA. Additionally, we will be looking to see whether taking this treatment causes any unexpected side effects, and whether certain blood tests can inform us about your disease status in addition to your PSA. | http://clinicaltrials.gov/ct2/show/NCT00669656 - Retrieved November 2011 | USC/Norris Comprehensive Cancer Center | Currently recruiting | |
72 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00604526 | High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy | Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy | High dose rate (HDR) brachytherapy is a form of radiation treatment using temporary radioactive seeds. This is done by placing very tiny catheters or tubes into the prostate and then inserting temporary radioactive seeds, called Iridium 192, through these catheters. HDR brachytherapy gives precise radiation to the prostate with less radiation given to the normal tissues near the prostate. For patients who have been treated with external beam radiation to the prostate before, HDR brachytherapy can give radiation again to the prostate without exposing the normal tissues around the prostate to significantly more radiation. This may be safer than giving external beam radiation again. The purpose of this study is to test the safety of high dose rate temporary brachytherapy (HDR) for prostate cancer that has come back after external beam radiation. We want to find out what effects, good and/or bad, the treatment has on you and your recurrent prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00604526 - Retrieved November 2011 | Memorial Sloan-Kettering Cancer Center | Currently recruiting | |
73 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00913939 | High-Dose-Rate Brachytherapy | MRI-Guided HDR Brachytherapy for Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00913939 - Retrieved November 2011 | University Health Network, Toronto | Currently recruiting | |
74 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01194648 | High-Intensity Focused Ultrasound in Treating Patients With Localized Prostate Cancer | A Multi-Center Prospective Single Arm Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer | This phase II trial is studying high-intensity focused ultrasound in treating patients with localized prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01194648 - Retrieved November 2011 | University College London Hospitals | Currently recruiting | |
75 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00116142 | Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer | Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial | This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00116142 - Retrieved November 2011 | Dana-Farber Cancer Institute | Sanofi-Aventis | Currently recruiting |
76 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00002651 | Hormone Therapy in Treating Men With Stage IV Prostate Cancer | Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III | This randomized phase III trial is studying two different regimens of hormone therapy and comparing how well they work in treating men with stage IV prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00002651 - Retrieved November 2011 | Southwest Oncology Group | National Cancer Institute; NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organization for Research and Treatment of Cancer (EORTC) | Currently recruiting |
77 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01270880 | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy | Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy. | http://clinicaltrials.gov/ct2/show/NCT01270880 - Retrieved November 2011 | Barbara Ann Karmanos Cancer Institute | National Cancer Institute | Currently recruiting |
78 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01314118 | IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease | The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last. | http://clinicaltrials.gov/ct2/show/NCT01314118 - Retrieved November 2011 | Centocor Ortho Biotech Services, L.L.C. | Currently recruiting | |
79 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01123434 | Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients. | A Non-interventional Study of Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Chinese Prostate Cancer Patients. | The primary objective is to assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.The secondary objective is to assess the quality of life（QoL）of the high risk localised or locally advanced Chinese prostate cancer patients with immediate postoperative adjuvant hormonal treatment and get the information of immediate postoperative adjuvant hormonal treatment (including the regimen, dosage and duration). | http://clinicaltrials.gov/ct2/show/NCT01123434 - Retrieved November 2011 | AstraZeneca | Currently recruiting | |
80 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00963755 | Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer | Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00963755 - Retrieved November 2011 | University of Lausanne Hospitals | Advanced Accelerator Applications; Centre d'Imagerie Biomédicale (CIBM), Lausanne, Switzerland | Currently recruiting |
81 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01117935 | Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer | Study of Hypofractionated Intensity Modulated External Beam Therapy for the Treatment of Patients With Adenocarcinoma of the Prostate | This clinical trial studies intensity-modulated external beam radiation therapy in treating patients with prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01117935 - Retrieved November 2011 | Virginia Commonwealth University | Currently recruiting | |
82 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00951535 | Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer | A Prospective Phase II Dose Escalation Trial Using IMRT and IGRT for T1a-T3cN0M0 Prostate Cancer | This phase II trial is studying how well intensity-modulated radiation therapy works in treating patients with stage I, stage II, or stage III prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00951535 - Retrieved November 2011 | All Ireland Cooperative Oncology Research Group | Currently recruiting | |
83 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer | This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer | http://clinicaltrials.gov/ct2/show/NCT01093183 - Retrieved November 2011 | University of Nebraska | National Cancer Institute | Currently recruiting |
84 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01183663 | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT01183663 - Retrieved November 2011 | M.D. Anderson Cancer Center | Celgene Corporation | Currently recruiting |
85 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01163084 | Leuprolide Acetate or Goserelin With or Without GDC-0449 Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate | This randomized phase I/II trial is studying giving leuprolide acetate or goserelin together with or without GDC-0449 followed by surgery to see how well they work in treating patients with locally advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01163084 - Retrieved November 2011 | M.D. Anderson Cancer Center | National Cancer Institute | Currently recruiting |
86 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01105338 | Lycopene or Green Tea in Treating Patients With Prostate Cancer Previously Enrolled on RADCLIFFE-PROTECT and Currently Enrolled on CRUK-ProMPT | ProDiet - Prostate and Diet Study | This randomized phase II trial is studying lycopene to see how well it works compared with green tea in preventing prostate cancer in patients previously enrolled on RADCLIFFE-PROTECT and currently enrolled on CRUK-ProMPT. | http://clinicaltrials.gov/ct2/show/NCT01105338 - Retrieved November 2011 | University of Bristol | Currently recruiting | |
87 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01243385 | Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | Metformin in Castration Resistant Prostate Cancer. A Multicenter Phase II Trial. | This phase II trial is studying the safety of giving metformin hydrochloride as first-line therapy in treating patients with locally advanced or metastatic prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT01243385 - Retrieved November 2011 | Swiss Group for Clinical Cancer Research | Currently recruiting | |
88 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01050504 | Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer | Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT01050504 - Retrieved November 2011 | Fred Hutchinson Cancer Research Center | Currently recruiting | |
89 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00775866 | MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy | MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy | In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation therapy in order to map out the location of the recurrence. Using this technique, we will be able to measure the accuracy of MR images in identifying the site of tumour recurrence. | http://clinicaltrials.gov/ct2/show/NCT00775866 - Retrieved November 2011 | University Health Network, Toronto | U.S. Army Medical Research and Materiel Command | Currently recruiting |
90 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00734851 | Multimodality Phase II Study in Prostate Cancer | Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study | This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy for prostate cancer. The primary aim is the rate of progression-free survival at 2 years as measured by lack of PSA progression and no evidence of disease. We hypothesize that this aggressive initial systemic therapy will improve the long term remission rates for men who are undergoing salvage radiation therapy for PSA recurrence in the absence of metastatic disease. | http://clinicaltrials.gov/ct2/show/NCT00734851 - Retrieved November 2011 | Duke University | Pfizer; Sanofi-Aventis | Currently recruiting |
91 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01320735 | Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia | Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation | 300 eligible patients with advanced prostate cancer will be enrolled at 33 sites in Russia. Study medication will be administered by subcutaneous or intramuscularly injection every 28 days. Planned induction therapy at least 6-9 months. When the prostate specific antigen decreases by > 90% from baseline or becomes lower than 4.0ng/ml the patients are included into intermittent hormone therapy group. Patients with prostate specific antigen decrease not achieved > 90% from baseline or down to values of 4.0 ng/ml or lower are withdrawn from the trial: they will receive standard-of-care. | http://clinicaltrials.gov/ct2/show/NCT01320735 - Retrieved November 2011 | Abbott | Currently recruiting | |
92 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00996749 | Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer | Pilot Study to Determine the Optimal Dosage of Omega-3 Polyunsaturated Fatty Acid (PUFA) in Men With Advanced Prostate Cancer | This clinical trial studies omega-3 fatty acids in treating patients with advanced prostate cancer. | http://clinicaltrials.gov/ct2/show/NCT00996749 - Retrieved November 2011 | Wake Forest University | National Cancer Institute | Currently recruiting |
93 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00874211 | Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases | A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment | This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases. | http://clinicaltrials.gov/ct2/show/NCT00874211 - Retrieved November 2011 | Southwest Oncology Group | National Cancer Institute | Currently recruiting |
94 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00957606 | Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer | Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer: Symptoms, Risc Factors, and Prevention | The purpose of this study is to: •to determine the rate of osteoporosis among patients with advanced prostate cancer; •to propose an algorithm for early detection of patients with advanced prostate cancer who are at risk of developing osteoporosis. | http://clinicaltrials.gov/ct2/show/NCT00957606 - Retrieved November 2011 | Odense University Hospital | University Hospital Roskilde; University Hospital Koge | Currently recruiting |
95 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00634582 | Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases | Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer | This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and bone metastases. | http://clinicaltrials.gov/ct2/show/NCT00634582 - Retrieved November 2011 | Wake Forest University | National Cancer Institute | Currently recruiting |
96 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00945477 | Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade | A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist. | Refer to clinical website. | http://clinicaltrials.gov/ct2/show/NCT00945477 - Retrieved November 2011 | Illinois CancerCare, P.C. | Currently recruiting | |
97 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01172028 | Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients | This phase I trial is studying the side effects and best dose of giving pemetrexed disodium and docetaxel together in treating patients with advanced solid tumors. | http://clinicaltrials.gov/ct2/show/NCT01172028 - Retrieved November 2011 | University of Arizona | National Cancer Institute | Currently recruiting |
98 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01304485 | PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma | Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse | Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy | http://clinicaltrials.gov/ct2/show/NCT01304485 - Retrieved November 2011 | Arizona Molecular Imaging Center | Currently recruiting | |
99 | #REF! | http://clinicaltrials.gov/ct2/show/NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer | The purpose of this study is to determine if patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo | http://clinicaltrials.gov/ct2/show/NCT01057810 - Retrieved November 2011 | Bristol-Myers Squibb | Currently recruiting | |
100 | #REF! | http://clinicaltrials.gov/ct2/show/NCT00635596 | Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (MT110-101) | An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment | This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors. | http://clinicaltrials.gov/ct2/show/NCT00635596 - Retrieved November 2011 | Micromet GmbH | Currently recruiting | |